InVivoPlus anti-mouse 4-1BB (CD137)

Qi X, Li F, Wu Y, et al. Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity. Nat Commun. 2019,10(1):2141. doi: 10.1038/s41467-019-10088-1

Bartkowiak T, Singh S, Yang G, et al. Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc Natl Acad Sci U S A. 2015,112(38):E5290-9. doi: 10.1073/pnas.1514418112

Dai M, Yip YY, Hellstrom I, et al. Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. Clin Cancer Res. 2015,21(5):1127-38. doi: 10.1158/1078-0432.CCR-14-1339

Murphy JT, Burey AP, Beebe AM, et al. Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice. Blood. 2014,123(14):2172-80. doi: 10.1182/blood-2013-12-544742

Wei H, Zhao L, Li W, et al. Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS One. 2013,8(12):e84927. doi: 10.1371/journal.pone.0084927

Guo Z, Cheng D, Xia Z, et al. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer. J Transl Med. 2013,11:215. doi: 10.1186/1479-5876-11-215

Dai M, Wei H, Yip YY, et al. Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation. J Immunother. 2013,36(4):248-57. doi: 10.1097/CJI.0b013e3182943549

Manzke N, Akhmetzyanova I, Hasenkrug KJ, et al. CD4+ T cells develop antiretroviral cytotoxic activity in the absence of regulatory T cells and CD8+ T cells. J Virol. 2013,87(11):6306-13. doi: 10.1128/JVI.00432-13

Kwong B, Gai SA, Elkhader J, et al. Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Res. 2013,73(5):1547-58. doi: 10.1158/0008-5472.CAN-12-3343

Curran MA, Kim M, Montalvo W, et al. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One. 2011,6(4):e19499. doi: 10.1371/journal.pone.0019499